



Cite this: *RSC Adv.*, 2019, 9, 26176

# Molecular docking, pharmacophore based virtual screening and molecular dynamics studies towards the identification of potential leads for the management of *H. pylori*†

Manoj G. Damale,<sup>a</sup> Rajesh B. Patil,<sup>\*b</sup> Siddique Akber Ansari,<sup>c</sup> Hamad M. Alkahtani,<sup>ID c</sup> Abdulrahman A. Almehizia,<sup>ID c</sup> Devanand B. Shinde,<sup>d</sup> Rohidas Arote<sup>e</sup> and Jaiprakash Sangshetti<sup>ID \*f</sup>

The enzyme pantothenate synthetase panC is one of the potential new antimicrobial drug targets, but it is poorly characterized in *H. pylori*. *H. pylori* infection can cause gastric cancer and the management of *H. pylori* infection is crucial in various gastric ulcers and gastric cancer. The current study describes the use of innovative drug discovery and design approaches like comparative metabolic pathway analysis (Metacyc), exploration of database of essential genes (DEG), homology modelling, pharmacophore based virtual screening, ADMET studies and molecular dynamics simulations in identifying potential lead compounds for the *H. pylori* specific panC. The top ranked virtual hits STOCK1N-60270, STOCK1N-63040, STOCK1N-44424 and STOCK1N-63231 can act as templates for synthesis of new *H. pylori* inhibitors and they hold a promise in the management of gastric cancers caused by *H. pylori*.

Received 2nd May 2019  
Accepted 9th August 2019

DOI: 10.1039/c9ra03281a

rsc.li/rsc-advances

## 1 Introduction

The *Helicobacter pylori* infection in the patients with chronic gastritis and peptic ulcer can become the primary cause of gastric cancer.<sup>1–5</sup> Gastric cancer is the fourth common malignancy worldwide causing over 700 000 deaths per year. *H. pylori* is a microaerophilic, spiral-shaped Gram-negative bacterium which colonizes in the human stomach eventually causing duodenal and gastric ulcers. Broad spectrum antibacterials and antibiotics such as metronidazole, clarithromycin, levofloxacin, amoxicillin, tetracycline, furazolidone, and rifabutin are used in the treatment and management of *H. pylori* infection. Unfortunately, the efficacy of these antibiotics against *H. pylori* has weakened due to a strong resistance developed by *H.*

*pylori* organism.<sup>6,7</sup> Furthermore, many factors such as the strain of *H. pylori*, the host genetic factor like polymorphism in the interleukin-1, gender, and individual's habits like smoking and their diet may aggravate the *H. pylori* infection. It is established that the colonization of the *H. pylori* with the nitro sating bacteria in the achlorhydric stomach becomes the primary cause of gastric cancer.<sup>8</sup> Therefore, eradication of the *H. pylori* infection and proper management and treatment of the duodenal and gastric ulcers is essential in the prevention of ensuing gastric cancer. Emergence of strong resistance is the main concern with most of the currently used broad spectrum antibacterials and antibiotics in *H. pylori* infection. Hence, design and development of the newer potential drug candidates effective against the newer targets specific for *H. pylori* may be advantageous. The enzyme pantothenate synthetase, encoded by the panC gene, catalyzes the biosynthesis of pantothenate (vitamin B5) from an adenosine triphosphate (ATP)-dependent condensation of the D-pantoate and the β-alanine in bacteria.<sup>9</sup> The pantothenate is a key precursor of the coenzyme A and the acyl carrier protein. Many intracellular processes such as fatty acid metabolism, cell signaling, synthesis of the polypeptides and the non-ribosomal peptides are regulated by the coenzyme A and the acyl carrier protein. Interestingly, mammals lack the pantothenate synthetase and its biosynthetic pathway and derive the pantothenate from their diet.<sup>10</sup> Thus, it is advantageous to target bacterium specific pantothenate

<sup>a</sup>Department of Pharmaceutical Medicinal Chemistry, Srinath College of Pharmacy, Aurangabad, M.S. 431136, India

<sup>b</sup>Sinhgad Technical Education Society's, Smt. Kashibai Navale College of Pharmacy, Kondhwa (Bk), Pune, India. E-mail: rajshama1@yahoo.com

<sup>c</sup>Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Po Box 2454, Riyadh 11451, Saudi Arabia


<sup>d</sup>Shivaji University, Vidyanagar, Kolhapur 416004, MS, India

<sup>e</sup>Department of Molecular Genetics, School of Dentistry, Seoul National University, Seoul, Republic of Korea

<sup>f</sup>Y. B. Chavan College of Pharmacy, Dr Rafiq Zakaria Campus, Rauza Baugh, Aurangabad, MS, India. E-mail: jnsangshetti@rediffmail.com

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c9ra03281a




Table 1 *M. tuberculosis* panC inhibitors from the literature

Compound no.	Scaffold	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X
1	A			—	—
2	A			—	—
3	A			—	—
4	A			—	—
5	A			—	—




Table 1 (Contd.)



Compound no.	Scaffold	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X
6	A			—	—
7	A			—	—
8	A			—	—
9	A			—	—
10	A	—NO <sub>2</sub>		—	—
11	A	—H	—H	—	—




Table 1 (Contd.)



Compound no.	Scaffold	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X
12	A	-NO <sub>2</sub>		—	—
13	A	-NO <sub>2</sub>		—	—
14	A	-NO <sub>2</sub>		—	—
15	B	-H	(CH <sub>3</sub> ) <sub>3</sub> CNH-		C
16	B	CH <sub>3</sub>	(CH <sub>3</sub> ) <sub>3</sub> CNH-		C
17	B	—	(CH <sub>3</sub> ) <sub>3</sub> CNH-		N
18	B	-H			C
19	B	CH <sub>3</sub>			C




Table 1 (Contd.)



Compound no.	Scaffold	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X
20	B	—			N
21	B	-H	(CH <sub>3</sub> ) <sub>3</sub> CNH-		C
22	B	CH <sub>3</sub>	(CH <sub>3</sub> ) <sub>3</sub> CNH-		C
23	B	—	(CH <sub>3</sub> ) <sub>3</sub> CNH-		N
24	B	-H			C
25	B	CH <sub>3</sub>			C
26	B	—			N
27	B	-H	(CH <sub>3</sub> ) <sub>3</sub> CNH-		C
28	B	CH <sub>3</sub>	(CH <sub>3</sub> ) <sub>3</sub> CNH-		C




Table 1 (Contd.)



Compound no.	Scaffold	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X
29	B	—	(CH <sub>3</sub> ) <sub>3</sub> CNH—	H <sub>3</sub> CO—	N
30	B	—H	—NH—	H <sub>3</sub> CO—	C
31	B	CH <sub>3</sub>	—NH—	H <sub>3</sub> CO—	C
32	B	—	—NH—	H <sub>3</sub> CO—	N
33	B	—H	(CH <sub>3</sub> ) <sub>3</sub> CNH—	H	C
34	B	CH <sub>3</sub>	(CH <sub>3</sub> ) <sub>3</sub> CNH—	H	C
35	B	—	(CH <sub>3</sub> ) <sub>3</sub> CNH—	H	N
36	B	—H	—NH—	H	C
37	B	CH <sub>3</sub>	—NH—	H	C
38	B	—	—NH—	H	N
39	B	—H	(CH <sub>3</sub> ) <sub>3</sub> CNH—		C




Table 1 (Contd.)



Compound no.	Scaffold	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X
40	B	-H	(CH <sub>3</sub> ) <sub>3</sub> CNH-		C
41	B	-	(CH <sub>3</sub> ) <sub>3</sub> CNH-		N
42	B	-H	-NH-		C
43	B	CH <sub>3</sub>	-NH-		C
44	B	-	-NH-		N
45	C	-H		-	-
46	C	-H		-	-
47	C	-H		-	-




Table 1 (Contd.)



Compound no.	Scaffold	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X
48	C	-H		—	—
49	C	-H		—	—
50	C	-H		—	—
51	C	-H		—	—
52	C	-H		—	—
53	C	-H		—	—
54	C	-H		—	—




Table 1 (Contd.)



Compound no.	Scaffold	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X
55	C	-H		—	—
56	C	-CH <sub>3</sub>		—	—
57	C	-CH <sub>3</sub>		—	—
58	C	-CH <sub>3</sub>		—	—
59	C	-CH <sub>3</sub>		—	—
60	C	-CH <sub>3</sub>		—	—
61	C	-CH <sub>3</sub>		—	—




Table 1 (Contd.)



Compound no.	Scaffold	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X
62	C	-CH <sub>3</sub>		—	—
63	C	-CH <sub>3</sub>		—	—
64	C	-CH <sub>3</sub>		—	—
65	C	-CH <sub>3</sub>		—	—
66	C	-CH <sub>3</sub>		—	—
67	D	-H		—	—




Table 1 (Contd.)



Compound no.	Scaffold	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X
68	D	-H		—	—
69	D	-H		—	—
70	D	-H		—	—
71	D	-H		—	—
72	D	-CH <sub>3</sub>		—	—
73	D	-CH <sub>3</sub>		—	—
74	D	-CH <sub>3</sub>		—	—




Table 1 (Contd.)



Compound no.	Scaffold	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X
75	D	-CH <sub>3</sub>		—	—
76	D	-CH <sub>3</sub>		—	—
77	D	-Cl		—	—
78	D	-Cl		—	—
79	D	-Cl		—	—
80	D	-Cl		—	—
81	D	-Cl		—	—




Table 1 (Contd.)



Compound no.	Scaffold	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X
82	D	-Br		—	—
83	D	-Br		—	—
84	D	-Br		—	—
85	D	-Br		—	—
86	D	-Br		—	—
87	D	-C <sub>2</sub> H <sub>5</sub>		—	—
88	D	-C <sub>2</sub> H <sub>5</sub>		—	—
89	D	-C <sub>2</sub> H <sub>5</sub>		—	—




Table 1 (Contd.)



Compound no.	Scaffold	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X
90	D	-C <sub>2</sub> H <sub>5</sub>		—	—
91	D	-C <sub>2</sub> H <sub>5</sub>		—	—
92	D	-C <sub>3</sub> H <sub>7</sub>		—	—
93	D	-C <sub>3</sub> H <sub>7</sub>		—	—
94	D	-C <sub>3</sub> H <sub>7</sub>		—	—
95	D	-C <sub>3</sub> H <sub>7</sub>		—	—
96	D	-C <sub>3</sub> H <sub>7</sub>		—	—
97	E			—	—
98	E			—	—




Table 1 (Contd.)



Compound no.	Scaffold	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X
99	E			—	—
100	E			—	—
101	E			—	—
102	E			—	—
103	E			—	—
104	E			—	—




Table 1 (Contd.)



Compound no.	Scaffold	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X
105	E			—	—
106	E			—	—
107	E			—	—
108	E			—	—
109	E			—	—
110	E			—	—



Table 1 (Contd.)



Compound no.	Scaffold	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X
111	E			—	—
112	E			—	—
113	E			—	—
114	E			—	—
115	E			—	—

synthetase in the development of potential inhibitors. Many experimental crystal structures of pantothenate synthetase are available which could be exploited in design and development of its potential inhibitors. But, most of these crystal structures and inhibitors are reported for the

*Mycobacterium tuberculosis*. To best of our knowledge the *H. pylori* specific panC inhibitors has not been reported so far and may be due to the unavailability of the experimental crystal structure of the *H. pylori* specific pantothenate synthetase. The complete genome sequencing has





Fig. 1 Sequence alignment of model and template.

identified the key proteins of *H. pylori*.<sup>11–13</sup> The European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI)<sup>14</sup> has assigned the accession number to gene of *H. pylori* panC as EBI-7515141 and the details of the interactions and protein features are available in UniProtKB database with ID P56061.<sup>15</sup> In absence of the experimentally solved crystal structure, homology modeling is the most reliable method to construct the theoretical models of proteins under study.<sup>16</sup> The homology modeling derived validated theoretical models of proteins can be used in molecular docking studies, which is the most popular technique to understand the binding mode and the affinities of ligands at the binding site of such proteins.<sup>17</sup> In fact, such molecular modeling approaches has lead to identification of many potential anti-cancer agents.<sup>18–22</sup> Furthermore, the best binding modes of the ligands with high affinity and the structural traits of such ligands can be used

to build the pharmacophore.<sup>23,24</sup> The features in such pharmacophore are usually exploited in the virtual screening which is an efficient and alternative approach to the High Throughput Screening to derive the promising hits.<sup>25–27</sup> The deeper insights into the binding modes and energetic of such hits at the binding site of the modeled protein in simulated biological environment can be achieved through molecular dynamics simulations. The effects and risk of the promising hits can be accessed through the prediction of absorption, distribution, metabolism, elimination and toxicity (ADMET) parameters which aid in the design of drug like compounds.<sup>28,29</sup> The fact that the inhibitors of the *H. pylori* specific pantothenate synthetase could be the best way to tackle the problem of poor prognosis of the *H. pylori* infection and the associated risk of the gastric cancer provoked us to investigate the computational aspects of this issue and provide the possible candidate




Fig. 2 Structural alignment of homology model and template structure (A)  $\alpha$  backbone alignment; (B) all atom alignment.






Fig. 3 Structure validation parameter Ramachandran plot and ProSa Z score of model structure.

molecules as inhibitors. Thus, the present work describes the homology modeling of the *H. pylori* specific pantothenate synthetase, the molecular docking studies with the known inhibitors, the pharmacophore development from the best docked poses of the top rank compounds, pharmacophore based virtual screening, the ADMET studies and the detail investigation of the possible mechanism of inhibition through the molecular dynamics simulations of the best hit molecules.

## 2 Materials and methods

### 2.1 Homology modeling

The *H. pylori* specific metabolic pathways were identified from the MetaCyc Metabolic Pathway Database (<https://metacyc.org/>).<sup>30–32</sup> The key enzymes in these pathways were further identified with the help of choke point finder tool available in this database. The database of essential genes (DEG) (<http://www.essentialgene.org/>)<sup>33</sup> was also explored to identify the essential genes and the corresponding metabolic enzymes in the *Helicobacter pylori*. The sequence of the key metabolic enzymes thus identified was retrieved from the Uniprot database (<https://www.uniprot.org/>).<sup>15,34</sup> This protein sequence was subjected to the BLASTP search in order to identify the matching protein.<sup>35</sup> These preliminary investigations lead to the identification of pantothenate synthetase, the unique protein specific for the *H. pylori*. The primary sequence of the panC specific for the *H. pylori* (Uniprot accession number P56061) was subjected to the similarity search in the Molecular Operating Environment (MOE).<sup>36</sup> The similarity search was executed by transferring the sequence in the sequence query and with the search parameters set to the values for gap start  $-12$ , gap extend  $-2$ ,  $E$ -value cutoff 10,  $E$ -value accept 0.5,  $Z$  iterations 100 and  $Z$  cutoff 6. Subsequently, the MOE homology model tool

linked with Generalized Born/Volume Integral (GB/VI) scoring function and Amber99 force field was used to generate the homology models.<sup>37</sup> MOE's site finder promodel module was employed to identify and validate the binding site. In this module the atoms on the protein's surface were identified, and the centers of spheres defined by combinations of four such points are marked. The clusters of such spheres defined the potential binding sites on the protein's surface, or voids within it. The likelihood of a hydrophilic contact was marked and this method identified 10 potential binding sites amongst which the first was used in the docking studies. Further validation of these




Fig. 4 PanC binding site residues predicted by site finder module of MOE.



Table 2 Docking and re-docking results

Comp. no.	Docking score (kcal mol <sup>-1</sup> )	Redocking score (kcal mol <sup>-1</sup> )	Interacting residues	Kinds of interactions		
				H-Bond	vdW	Pi
1	-4.23	-4.6	GLN58, GLN153, ARG187	3	0	1
2	-4.07	-4.34	MET27, GLU63, TYR68, ASN62, GLU117	3	1	2
3	-4.1	-4.29	HIS34, LEU116, ASP150, SER186, LEU271	2	1	4
4	-4.81	-4.9	MET27, TYR68, ASP150, LEU271, ARG121, LEU117, TYR238	3	1	2
5	-4.25	-4.33	MET27, GLN58, GLN153, ARG121	3	1	2
6	-5.1	-5.19	MET27, HIS24, GLU64, ASN62, ARG121, GLN58, GLN153, GLU117	4	1	3
7	-5.12	-5.39	HIS34, HIS124, ARG121, ASP150, LYS149	2	1	5
8	-4.57	-4.63	MET27, GLU63, TYR68, ASN62, ARG121	3	1	3
9	-5.03	-5.22	HIS31, HIS34, LYS149, SER186, ARG269, ARG187, SER185	6	3	3
10	-6.08	-6.24	PRO25, MET27, HIS34, LEU116, ARG269, ARG121, ASP150, GLN153	6	2	1
11	-4.71	-4.87	API50, LEU271, LEU260, ARG269	3	1	2
12	-4.7	-4.71	MET27, LEU116, ARG121, ARG269, GLN153, HIS124	5	1	1
13	-4.91	-5.01	MET27, HIS34, SER185, SER186, ARG187, ARG269	4	1	2
14	-4.54	-4.57	GLY28, HIS34, LYS149, LEU271, ARG269	4	1	1
15	-4.8995	-3.6702	HIS124, ASP150, ARG269, LYS149, LEU271	2	3	2
16	-4.2209	-4.9713	HIS124, ASP150, LEU271	2	1	2
17	-5.8087	-5.756	MET27, GLU63, HIS124, ARG187	1	1	3
18	-5.2863	-5.39	HIS124, ASP150, ARG187, ARG269, LEU271	2	1	4
19	-5.1268	-5.6967	MET27, PHE59, LYS149, ARG187, HIS124, ARG187	1	1	4
20	-4.0056	-4.1323	MET27, PHE59, TYR68, GLU63, ARG269, GLN159, GLN58	3	1	4
21	-4.2869	-4.3971	HIS124, ASP150, LEU271	2	1	1
22	-4.4866	-4.7215	MET27, PHE59, TYR68, HIS124, LEU271, ASP150	2	1	4
23	-4.6603	-4.6689	PHE59, HIS124, ASP150, LEU271	2	1	2
24	-5.8087	-5.9781	PRO25, MET27, LEU37, HIS34, PHE146, GLY147, VAL132	2	1	6
25	-4.8805	-5.0012	MET27, HIS34, PHE125, HIS124, ARG187	2	2	3
26	-4.27	-4.6732	GLU63, ARG269, LEU271, LEU260	2	1	2
27	-3.9108	-4.2996	TYR68, ARG187	2	1	0
28	-4.3609	-4.9383	GLU63, ARG121, HIS124	1	1	4
29	-4.4464	-4.4861	GLN58, HIS124, LEU271, ASP150	2	1	2
30	-4.4241	4.6267	GLN58, ASP150, LYS149, ARG269, LEU271	3	1	2
31	-5.2496	-5.342	MET27, TYR68, ARG187, HIS124, ARG121, GLN152, LEU116	3	2	2
32	-5.11	-5.1287	MET27, GLY28, HIS31, ALA29, HIS34, ARG187, SER186, TYR68	4	1	5
33	-3.6937	-3.8271	ASP150, LEU271	1	1	1
34	-3.935	-4.135	HIS124, LEU271, ASP150	2	1	2
35	-3.747	-3.8005	MET27, HIS34, ASP150, GLN153	3	1	1
36	-4.954	-4.991	ARG121, ASP150, LEU271	2	1	3
37	-4.6733	-4.7029	ASP150, ARG269, LEU271	1	1	3
38	-4.5544	-4.6281	ARG121, ASP150, ALA151, LEU160, LEU271	4	1	3
39	-4.2869	-4.3187	GLU63, ARG121, HIS124	3	1	2
40	-3.9108	-4.0013	GLU63, ARG269, LEU260	1	1	2
41	-4.4464	-4.4556	GLN58, HIS124, LEU271, ASP150	2	1	3
42	-3.935	-4.1032	HIS124, LEU271, ASP150	1	1	1
43	-4.954	-5.0031	MET27, HIS34, PHE125, HIS124, ARG187	2	1	2
44	-4.6733	-4.7631	MET27, HIS34, HIS124, ARG187	2	1	1



Table 2 (Contd.)

Comp. no.	Docking score (kcal mol <sup>-1</sup> )	Redocking score (kcal mol <sup>-1</sup> )	Interacting residues	Kinds of interactions		
				H-Bond	vdW	Pi
45	-3.57	-3.66	TYR68, ASP150, LEU271, SER186, ARG187	3	1	1
46	-4.78	-4.81	HIS34, HIS124, PHE125, ALA151, LEU271, LEU260, ASP150, ARG269, LEU271	4	1	5
47	-4.08	-4.12	GLU63, ALA151, GLN152, GLN153, ARG121, LYS149, HIS124	4	1	2
48	-4.84	-4.93	LEU116, ARG121, ALA151, LYS149, ALA183, LEU270, ARG269	5	1	5
49	-4.16	-4.14	PRO69, ALA29, TYR68, ASP150, SER186, TYR190, LEU271, ARG187	2	1	3
50	-4.38	-4.14	ALA29, MET27, GLN58, HIS124, ASP150, ARG187, LYS149, SER185, SER186	4	2	4
51	-4.39	-4.41	TYR68, ASP150, LEU271, SER186, ARG187, HIS124, GLN153, LYS149	5	1	5
52	-4.25	-4.31	MET27, TYR68, LYS149, VAL176, SER185, SER186	4	1	4
53	-5.84	-5.91	PRO25, TYR26, ALA29, HIS34, GLN153, GLY147, ASP150, SER186	3	1	3
54	-5.79	-5.789	ARG121, LYS149, GLN152, ASN183, LEU270, LEU271, ARG269	3	1	4
55	-5.93	-6.01	HIS34, LYS149, SER185, ARG187, ARG269, LEU271	3	0	3
56	-5.68	-5.79	MET27, PHE59, TYR68, ARG187, ASP150, LEU271	3	1	4
57	-5.77	-5.87	PRO25, MET27, HIS31, HIS34, LEU37, SER187, VAL128, VAL132, SER186, GLY147	3	2	4
58	-4.63	-4.76	MET27, GLU63, TYR68, GLN153, ARG121	3	1	3
59	-5.1	-5.12	PRO25, MET27, HIS34, MET135, ILE131, ARG187, ARG269	2	2	4
60	-4.05	-4.21	HIS34, TYR68, PHE271	1	1	2
61	-5.33	-5.39	MET27, GLN58, HIS124, VAL128, TYR145, GLY147, ASP150, GLN153, LEU271	4	1	3
62	-5.15	-5.21	PRO25, MET27, THR26, ILE131, MET135, LYS149, GLN153	4	2	2
63	-7.7	-7.79	GLN58, GLU63, GLN153, ARG121, TYR68	5	1	1
64	-5.02	-5.19	TYR68, ASP150, GLN152, ARG269, SER186	3	2	2
65	-3.96	-4.18	HIS34, ARG187, ASP150, GLN152, LEU271	1	1	4
66	-4.13	-4.19	PRO25, MET27, HIS31, SER187, ILE131, ARG187, MET135	1	2	3
67	-2.8687	-2.8729	PHE59, TYR58, HIS124, ASP150, ARG187, LEU271	4	1	3
68	-3.3455	-3.4411	LEU30, HIS31, HIS34, LYS149, SER185	3	1	3
69	-4.7611	-4.812	LEU30, HIS31, HIS34, LYS149, SER185	3	1	3
70	-4.1494	-4.4271	LEU30, HIS34, LYS149, SER185, SER186, ARG187	4	1	4
71	-3.6942	-3.7316	GLU63, PHE125, ARG121, HIS124, ARG269	2	1	3
72	-4.2448	-4.3993	MET27, HIS31, HIS34, LYS149, SER185, ARG187	3	1	4
73	-3.5961	-3.6821	ASN62, GLU63, HIS124, PHE125, ARG187, ARG269	3	1	3
74	-5.7105	-5.7389	GLY60, ALA61, ASN62, GLU63, LYS149, ARG187, ARG269, ASN271, ARG121	6	1	3
75	-4.1277	-4.1791	MET27, HIS31, HIS34, LYS149, SER185, ARG187, LEU271	2	1	4
76	-3.9968	-4.156	MET27, HIS34, ASP150, LEU271	1	1	3



Table 2 (Contd.)

Comp. no.	Docking score (kcal mol <sup>-1</sup> )	Redocking score (kcal mol <sup>-1</sup> )	Interacting residues	Kinds of interactions		
				H-Bond	vdW	Pi
77	-5.0105	-5.1995	ASN62, GLU63, ARG121, ARG187, ARG269	3	1	3
78	-6.1995	-6.2677	ASN62, GLU63, ARG121, LYS149, SER185, ARG187, ARG269	8	1	3
79	-3.3602	-3.3871	LYS149, ALA183, SER185, ARG187, ARG269, LEU271, ILE202, LEU182	4	2	3
80	-4.2577	-4.3289	PRO25, MET27, GLY28, HIS31, GLY33, HIS34, LYS149, LEU184	4	1	2
81	-4.3562	-4.3891	PRO25, HIS31, GLY33, HIS34, LYS149, LEU184	2	2	6
82	-4.8416	-4.9562	GLN58, GLU63, TYR68, HIS124, ARG269, ARG187	3	1	2
83	-4.8644	-4.9493	GLU63, GLN58, ASP64, TYR68, HIS124, ARG269, ARG187	3	1	4
84	-4.0638	-4.1452	MET27, PHE59, TYR68, ARG187	2	1	2
85	-5.323	-5.3671	GLY28, ALA29, HIS34, SER185, LYS149, ARG269, ARG187, SER186, LEU184	5	1	3
86	-5.1447	-5.1591	HIS34, PHE59, TYR68, ARG187, LEU184	4	2	3
87	-3.2977	-3.3592	LYS149, SER185, ARG187, ARG269, LEU270, LEU271	3	1	3
88	-2.9499	-2.8429	MET27, GLU63, HIS124, VAL128, ARG187, ARG169	2	1	3
89	-4.4058	-4.4851	PHE59, PRO25, HIS31, GLY33, HIS34, LYS149, LEU184	2	2	6
90	-4.4837	-4.5201	MET34, LYS149, ALA183, SER185, ARG187, ARG269, LEU271, ILE202, LEU182	4	2	3
91	-2.011	-2.293	PHE59, TYR58, HIS124, ASP150, ARG187	1	1	2
92	-3.4441	-3.4896	LYS149, ALA183, SER185, ARG187, ARG269, LEU271, ILE202, LEU182	4	2	4
93	-2.9499	-2.9618	MET27, GLU63, HIS124, VAL128, ARG187, ARG169	2	1	3
94	-3.1448	-3.1844	MET27, HIS34, GLU63, HIS124, VAL128, ARG187, ARG169	2	1	4
95	-4.4864	-4.5891	PRO25, HIS31, HIS34, GLY33, HIS34, LYS149, LEU184, SER185	3	2	6
96	-2.9824	-3.3168	MET27, GLU63, HIS124, VAL128, ARG187, ARG169	2	1	4
97	-3.8659	-3.962	GLU63, ARG121, SER185, LEU271, HIS124	4	1	2
98	-4.5719	-4.782	PRO25, HIS34, LYS149, SER185, ARG187, ARG269, TYR238	4	1	3
99	-4.5506	-4.62	HIS34, LYS149, SER185, ARG187, ARG269, TYR238	3	1	3
100	-4.0345	-4.491	GLU63, ARG121, SER185, LEU271, HIS124	3	1	3
101	-4.8854	-4.887	PRO25, HIS31, HIS34, LYS149, SER185, ARG187, ARG269, TYR238	4	1	3
102	-3.7926	-3.8416	HIS34, ARG121, SER185, LEU271, HIS124	4	1	1
103	-5.305	-5.4591	PRO25, HIS31, HIS34, LYS149, SER185, ARG187, ARG269, TYR238, LEU271	5	1	4
104	-5.1502	-5.3819	PRO25, HIS34, LYS149, SER185, ARG187, ARG269, TYR238, LEU271	4	1	4
105	-5.831	-5.8702	PRO25, HIS31, HIS34, LYS149, SER185, SER186, ARG187, ARG269, TYR238	5	1	4
106	-6.0256	-6.0482	PRO25, HIS31, HIS34, LYS149, SER185, SER186, ARG187, ARG269, TYR238, LEU27	5	1	4
107	-4.8235	-4.8491	MET27, HIS31, HIS34, LYS149, SER185, ARG187, ARG269, TYR238	5	1	4



Table 2 (Contd.)

Comp. no.	Docking score (kcal mol <sup>-1</sup> )	Redocking score (kcal mol <sup>-1</sup> )	Interacting residues	Kinds of interactions		
				H-Bond	vdW	Pi
108	-6.0962	-6.173	PRO25, MET27, HIS31, HIS34, LYS149, SER185, SER186, ARG187, ARG269, TYR238	6	1	4
109	-4.0069	-4.1639	HIS34, ARG121, SER185, LEU271, HIS124	3	1	3
110	-4.9985	-5.0173	MET27, HIS34, LYS149, SER185, ARG187, ARG269, TYR238	4	1	4
111	-4.9124	-5.0792	GLU63, GLN58, ASP64, TYR68, HIS124, ARG269, ARG187	3	1	4
112	-6.2852	-6.4021	PRO25, MET27, HIS31, HIS34, LYS149, SER185, SER186, ARG187, ARG269, TYR238	6	2	4
113	-5.1362	-5.1562	PRO25, HIS34, LYS149, SER185, ARG269, TYR238, LEU271	4	2	1
114	-5.7806	-5.8492	PRO25, HIS34, GLY60, LYS149, SER185, ARG187, ARG269, TYR238, LEU271	5	1	4
115	-4.7319	-4.872	PRO25, HIS34, LYS149, SER185, ARG187, ARG269, TYR238	4	1	3

models based on various computational approaches was carried out and the most suitable model was used in docking studies.

## 2.2 Molecular docking

Molecular docking studies were carried out on MOE molecular modeling suite. The validated homology model structure was subjected to the structure preparation wizard to curate the inaccuracies in the protein structure using the LigX standard protocol. The promodel module was used for the active site prediction. One hundred fifteen already known *M. tuberculosis* PanC inhibitors<sup>38–42</sup> were used for the docking studies (Table 1).

The 2D structures of these inhibitors were drawn in the LigX module and converted into the 3D conformers and subsequently subjected to the energy minimization step using MMFF force field. The docked structures were ranked as per their binding affinity score called as the *S*-score. Redocking experiment to judge and ensure the docking accuracy was also carried out using already optimized inhibitor structures and panC structure. The root mean square deviations and deviations in docking score were accounted in deciding the accuracy of docking protocol.

## 2.3 Pharmacophore modeling and virtual screening

The top ranked docked conformers of the known PanC inhibitors were used for the construction of the




Fig. 5 The binding pose and molecular interactions of inhibitor 63 into the active site of the model structure of the PanC.






Fig. 6 3D-pharmacophore models of the top docked hit **63** into the active site of the homology model of the PanC.

pharmacophore model.<sup>43</sup> The phase module of MOE was used to derive the pharmacophoric features on the basis of the structural and energy features of the protein and the inhibitors. The 3D pharmacophoric model thus generated having various pharmacophoric features was used for the virtual screening through virtual screening module of the MOE. The InterBioScreen natural database (<https://www.ibscreen.com/natural-compounds>)<sup>44,45</sup> consisting of 60 000 natural compounds was screened against this pharmacophore.

#### 2.4 ADMET analysis

The potential hits obtained in the virtual screening were subjected to the ADMET screening for the predication of drug-like properties with the FAF-Drug2 tool for the ADMET prediction.<sup>46</sup> Further, the data of the ADMET studies were filtered and validated for the Lipinski's rule of 5 and the Veber rule.<sup>47,48</sup> In the ADMET studies the values of TPSA (<100), log *P* (<5) and molecular weight (<500) indicates good oral bioavailability, whereas number of rotatable (<25), rigid bonds (<10) and number hydrogen bond acceptors (<10)/donors (<5) indicates good intestinal availability.

#### 2.5 Molecular dynamics (MD) simulation studies

The top-ranked hits with desired ADMET features were subjected to the MD simulations using Gromacs 5.1.2.<sup>49,50</sup> The remote server of the Bioinformatics Resources and Applications Facility (BRAAF), C-DAC, Pune was used to perform the production phase MD simulations. The topology of the protein was generated using the CHARMM36 all-atom force field<sup>51</sup> while the ligand topology was generated with the CHARMM General Force Field (CGenFF) from the CGenFF server available at <https://cgenff.paramchem.org>. After solvating the system with the simple point charge solvent-216 model in

a dodecahedral unit cell the system was neutralized with the addition of appropriate counter ions such as sodium and chloride. The system was subsequently energy minimized and equilibrated with respect to the constant volume and the pressure position restraint dynamics at a constant temperature of 300 K for 100 picoseconds. The system was subsequently subjected to the energy minimization in order to remove the steric clashes. Subsequently, the position restraint dynamics under NVT and NPT (constant volume and pressure) conditions at 300 K for 100 ps was carried out. During the 10 nanosecond production phase MD, the covalent bonds were restrained with the LINCS algorithm<sup>52</sup> and the long range electrostatics such as coulombic and Lennard Jones interaction energies were controlled with the cutoff value of 12 Å with the Particle Mesh Ewald method (PME).<sup>53</sup> The results of the MD were analyzed with the help of different modules in the GROMACS package.

#### Top Ranked Docked Complex




Fig. 7 Schematic representation of the virtual screening protocol.



Table 3 Systematic representation of *in silico* docking data of the top ranked virtual hits

Sr. no.	Hits_ID	Docking score (kcal mol <sup>-1</sup> )	Interacting residues	Kinds of interactions		
				H-Bond	vdW	Pi
1	STOCK1N-76518	-6.38	HIS34, GLU63, ARG121, HIS124, ASP150, ARG269, SER185, SER186, GLU271	4	3	3
2	STOCK1N-74127	-5.45	THR26, MET27, TYR68, HIS34, GLN58, ASP150, LYS149, SER187	3	3	2
3	STOCK1N-73916	-5.7	THR26, MET27, HIS34, GLN58, GLU63, LYS149, RG187	6	2	3
4	STOCK1N-71293	-5.81	THR26, MET27, GLY28, PRO25, ARG121, LYS149, ARG269, LEU271	4	2	2
5	STOCK1N-68553	-6.69	ASN62, GLU63, ARG121, ARG187, LEU271, ARG269	5	1	1
6	STOCK1N-67377	-7.87	HIS34, TYR68, ARG121, PHE125, HIS124, ASP150, SER185, TYR238, ARG269	5	2	5
7	STOCK1N-64449	-6.71	ARG121, HIS124, LYS149, ASP150, SER185, ARG187, ARG269	3	3	3
8	STOCK1N-64228	-6.07	PRO25, GLN58, ASP150, ARG269, GLN153	3	2	1
9	STOCK1N-63827	-8.27	PRO25, THR26, MET27, HIS34, GLN58, GLU63, LYS149, ARG187, LEU271	5	4	4
10	STOCK1N-63231	-8.67	TYR68, MET27, HIS124, ALA151, GLN152, ASP150, LYS149	6	1	4
11	STOCK1N-63040	-9.51	ASN62, GLU63, ARG121, GLN152, GLN153, ARG187, LEU271, ARG269	5	3	3
12	STOCK1N-60270	-10.7	LEU30, MET27, HIS34, TYR68, ARG121, ARG268, GLN153, ASP150, PHE146, GLN152, SER186, ARG269	6	1	4
13	STOCK1N-59730	-8.33	HIS34, TYR68, PHE125, GLU63, LYS149, ARG187, ARG269	3	3	3
14	STOCK1N-26126	-7.87	ARG121, LYS149, ASP150, SER185, SER186, ARG269, ARG187	6	1	1
15	STOCK1N-28765	-4.65	ARG121, ASP150, LYS149, SER185, SER186, ARG269	6	1	1
16	STOCK1N-32864	-7.46	PRO25, GLN58, ASP150, GLN153, ARG269	4	2	1
17	STOCK1N-36335	-4.49	PHE59, GLU63, ARG187, HIS124, ARG121, ARG269, LEU271	5	1	1
18	STOCK1N-44424	-8.91	TYR68, ARG121, PHE125, ASP150, ARG187, TYR238, ARG269, LEU271	6	2	3
19	STOCK1N-45307	-7.14	TYR68, MET27, HIS124, ALA151, GLN152, ASP150, LYS149	6	1	4
20	STOCK1N-45539	-6.39	ARG121, HIS124, LYS149, ASP150, SER185, ARG187, ARG269, LEU271	4	1	1

### 3 Results and discussion

#### 3.1 Homology modeling

The results of Metacyc analysis showed that total 144 unique metabolic pathways are present in the *H. pylori* with 570 known enzymes. Amongst these enzymes, 172 enzymes are unique to the *H. pylori*. Further, 24 enzymes amongst these unique enzymes serve as essential enzymes executing the respective metabolic pathway and can serve as promising targets in the drug design. The analysis of these enzymes suggested that the pantothenate synthetase (PanC, Pantoate- $\beta$ -alanine ligase) is unique to *H. pylori*, but not expressed in *Homo sapiens*. The identification of key genes responsible for the survival of the *H. pylori* through the database of essential

genes also revealed that PanC is one of the essential gene. The primary sequence of the panC with 276 amino acids was retrieved from the UniPort database. The results of the preliminary BLAST analysis suggest that best model has the sequence identity of 43.87% with the template of the X-ray crystallographic structure of the panC from *Thermotoga maritima* (PDB ID: 2EJC). The atomic resolution being the key parameter for the selection of the template structure, this template structure with atomic resolution 2.4 Å was found appropriate. Further, the full genomes of *H. pylori* and *T. maritima* were retrieved (<https://www.ncbi.nlm.nih.gov/genome>) and subjected to species variation studies. It was found that there is 25.4% species similarity suggesting the suitability of species for homology modeling. The differences






Fig. 8 The binding pose of top hits at binding site. (A) STOCK1IN 63040; (B) STOCK1IN 44424; (C) STOCK1IN 63231 and; (D) STOCK1IN 60270.

in the residue composition of the binding site of panC from *Thermotoga maritima* and homology model of *H. pylori* were also investigated. The binding site of panC from *T. maritima* constitutes the residues Pro28, Thr29, Met30, Gly31, Tyr32, Leu33, His34, His37, Leu40, Gln61, Glu66, Tyr71, Leu116,

Arg121, His124, Phe125, Tyr145, Phe146, Gly147, Lys149, Asp150, Ala151, Gln152, Gln153, Phe154, Leu157, Ser185, Ser186, Arg187, Tyr241, Arg272 and Ile274. All these residues are also part of the binding site of homology model of *H. pylori* except few differences such as absence of Tyr32, Phe154 and






Fig. 9 The docked conformers of ligand **63** (magenta) and top virtual hit STOCK1N-60270 (green) at the binding site.

Ile274 and presence of Ala29, Leu260 and Leu271. Sequence alignment of template and homology model has performed in MOE Sequence Editor in order to check the similarity and identity as shown in Fig. 1.

The homology models generated were subjected to the structure validation tools like Procheck, ProSA and SPDBV.<sup>54–56</sup> In order to validate the homology model the  $C\alpha$  deviation and all atom fit were calculated in SPDBV tool. The  $C\alpha$  deviation and all atom fit values 0.42 and 0.1 Å respectively suggest that the model structure is acceptable for further studies. The structural alignment of the homology model and template structure is shown in Fig. 2.

The final model was chosen in which the 99.2% of the residues were in the allowed region as shown in the Ramachandran plot (Fig. 3).

ProSA-web server provides the estimate of errors in experimental and theoretical models of the proteins. It uses the atomic co-ordinates of each residue of the protein and provides the  $Z$  score and residue score. The  $Z$  score is measure of overall quality of model protein and determined on the basis of  $Z$  scores of all experimentally determined protein chains in model protein. The  $Z$  score of final model was  $-7.84$  suggesting the overall good model quality. The results of binding site analysis through MOE's site finder module showed that the residues Pro25, Glu63, Gln58, Tyr68, Leu270, Leu271, Phe59, Gln153, His124, Phe125, Asp150, Leu271, Leu270, Ser185 and Lys149 are the key residues in the binding pocket which contribute to the various types of interactions with ligand (Fig. 4). The binding site of the final model correlated well with the binding site of the template structure and most of these residues are present at the binding site of both the structures.

### 3.2 Molecular docking

The identification of the key contributing residues in the binding pocket of the panC model was carried out by the measurement of the contribution of interaction energy of each residue with the ligand through the Promodel module of MOE-2013. During the docking studies all the known inhibitors (total 115 such inhibitors) of *M. tuberculosis* were docked into the binding site of the modeled *H. pylori* panC. The *M. tuberculosis* specific panC inhibitors were chosen because of diversity in the

Table 4 Pharmacokinetic parameters of virtual hits for good oral bioavailability<sup>a</sup>

Sr. no.	Ligand_ID	% ABS	MW	log $P$	TPSA	RotatableB	RigidB	HBD	HBA	Rings	Ratio H/C	Toxicity
1	STOCK1N-76518	77.15	467.51	4.39	92.32	9	24	1	7	2	0.31	Non toxic
2	STOCK1N-74127	81.52	354.36	2.27	79.65	7	19	0	6	2	0.37	Non toxic
3	STOCK1N-73916	86.73	425.48	4.45	64.55	4	30	0	5	3	0.23	Non toxic
4	STOCK1N-71293	76.16	356.33	2.94	95.20	6	19	1	7	2	0.37	Non toxic
5	STOCK1N-68553	80.64	260.29	2.08	82.19	6	13	3	3	1	0.36	Non toxic
6	STOCK1N-67377	59.45	519.59	4.48	143.63	8	28	5	5	2	0.36	Non toxic
7	STOCK1N-64449	82.55	266.29	1.84	76.66	6	10	2	4	1	0.46	Non toxic
8	STOCK1N-64228	78.99	431.44	4.81	87.00	6	26	1	6	3	0.28	Non toxic
9	STOCK1N-63827	61.59	543.57	2.73	137.43	7	34	4	7	4	0.33	Non toxic
10	STOCK1N-63231	67.47	453.44	3.42	120.39	8	25	2	8	2	0.38	Non toxic
11	STOCK1N-63040	62.68	507.54	2.24	134.27	8	29	3	7	3	0.37	Non toxic
12	STOCK1N-60270	49.96	485.57	3.07	171.13	13	14	5	8	1	0.48	Non toxic
13	STOCK1N-59730	67.47	455.46	3.32	120.39	9	21	2	8	2	0.38	Non toxic
14	STOCK1N-26126	85.43	514.70	3.57	68.31	2	33	0	5	3	0.23	Non toxic
15	STOCK1N-28765	76.94	269.26	1.88	92.93	3	17	2	5	2	0.54	Non toxic
16	STOCK1N-32864	67.47	389.36	2.66	120.39	8	16	2	8	2	0.47	Non toxic
17	STOCK1N-36335	61.49	587.74	2.33	137.71	3	37	5	8	3	0.27	Non toxic
18	STOCK1N-44424	72.49	401.45	3.51	105.84	9	19	2	6	1	0.32	Non toxic
19	STOCK1N-45307	73.31	417.42	2.30	103.46	4	30	2	6	2	0.41	Non toxic
20	STOCK1N-45539	71.14	473.52	5.46	109.75	6	31	2	6	3	0.25	Non toxic

<sup>a</sup> ABS – absorption; TPSA – topological polar surface area;  $n$ -ROTb – number of rotatable bonds; MV – molecular volume; MW – molecular weight; log  $P$  logarithm of partition coefficient;  $n$ ON – number of hydrogen bond acceptors;  $n$ -OHNH – number of hydrogen bonds donors.






Fig. 10 Structures of the top virtual hits.

scaffolds of these inhibitors. Further, these inhibitors were reported to bind at the catalytic site of *M. tuberculosis* panC where the pantoate and  $\beta$ -alanine substrates are processed to the

patothenate. A similar biochemical mechanism is expected at the binding site of *H. pylori* panC and for computational design such inhibitors can be a good starting point. The docking






Fig. 11 RMSD for panC (A) the backbone atoms and (B) the atoms of virtual hits.

results showed that the residues Pro25, Glu63, Gln58, Tyr68, Leu270, Leu271, Phe59, Gln153, His124, Phe125, Asp150, Leu271, Leu270, Ser185 and Lys349 are the key residues in the binding pocket which contribute to the various types of interactions with ligand. The analysis of docking interactions showed that the core scaffold of all the known inhibitors plays an important role in the key interactions. The details of the structures of all the known inhibitors with the docking scores, the interacting residues and the type of key interactions are provided in the Table 2.

The tetrahydropyrido thieno pyrimidin-4-one derivative **63** having the lowest binding free energy of  $-7.70$  kcal mol $^{-1}$  was found forming two hydrogen bond interactions with the nitrogen atoms of core scaffold and the residues Glu63 and Tyr68 and two hydrogen bond interactions with the oxygen atom of *o*-nitro substituent with the Gln58 and Gln153. This inhibitor also forms the hydrophobic  $\pi$ - $\pi$  stacking interaction between the phenyl ring and Arg121 (Fig. 5). The lowest binding free energy for this ligand may be due to such hydrogen bond formation and hydrophobic interaction. The

re-docking of the ligands produced similar interactions with slight variations in the docking scores suggesting the accuracy of docking protocol followed.

### 3.3 Pharmacophore-model construction and virtual screening

These pharmacophoric features provide the important insights of functionalities contributing in the molecular activity of the inhibitors. The key pharmacophoric features such as the hydrogen bond acceptor, the metal ligator, the aromatic ring, the hydrogen bond donor responsible for the inhibitory activity were identified. The pharmacophoric model was constructed on the basis of the key interactions of top ligands with the residues at the binding site of the PanC. For this purpose the set of predefined features such as hydrogen bond acceptor (HBA), aromatic ring (Aro) from such interactions were exploited. The mapping of developed 3D-pharmacophore model with the top docked hit **63** into the active site of the homology model of the PanC is shown in Fig. 6.

The results of the pharmacophore design suggest that the ligand **63** has four key pharmacophoric features namely two hydrogen bond acceptor sites (F1 & F3, designated as Acc), two aromatic rings (F2 & F4 designated as Aro). The best pharmacophore model was selected on the basis of the highest correlation coefficient, root mean square deviation (rmsd) values and *E*-value. As per the protocol shown in Fig. 7, virtual screening of InterBioScreen natural compounds database was carried out.

The pharmacophoric features F1-F4 were chosen as the filtering criteria during virtual screening. The virtual screening experiment gave 20 virtual hits as given in the Table 3.

The virtual hits thus obtained were subjected to docking studies to investigate the interactions at the binding site. The virtual hits STOCK1N-60270, STOCK1N-63040, STOCK1N-44424 and STOCK1N-63231 showed the lowest binding free energy of  $-10.1$ ,  $-9.51$ ,  $-8.91$  and  $-8.67$  kcal mol $^{-1}$  respectively in the docking studies. These virtual hits were found making key hydrogen bond and hydrophobic  $\pi$ - $\pi$  stacking interactions with residues such as Gln153, Tyr68, Glu63 and Arg121. The analysis of the docking score and the binding poses of the virtual hits it was observed that **STOCK1N-60270**, **STOCK1N-63040**, **STOCK1N-44424** and **STOCK1N-63231** are the best possible hits. The binding poses of these hit molecules at the binding site is shown in Fig. 8.

The hits with matching features of the best docked ligand may have the highest potential to inhibit the pantothenate synthetase of the *H. pylori*. The docked conformer of the tetrahydropyrido thieno pyrimidin-4-one derivative **63** having lowest binding free energy and the docked conformer of the potential virtual hit **STOCK1N-60270** overlaid at the binding site is shown in Fig. 9.

### 3.4 In silico ADME predictions

The drug-like properties has been predicted by analyzing absorption, distribution, metabolism, elimination and toxicity






Fig. 12 RMS fluctuations in the backbone atoms during the MD simulations.

risk characteristics. These characteristics are calculated and analyzed in terms of various physicochemical parameters and pharmaceutical properties using the FAFDrug2 ADMET prediction tool and the data is summarized in Table 4. The data obtained for the virtual hits with STOCK1N ID numbers 73916, 64228, 63827, 63231, 63040, 60270, 44424 and 45307 were found within the acceptable range of the ADMET criteria.

The value of the topological polar surface area (TPSA) and the log *P* of the hits indicate that they have very good oral bioavailability. The parameters like the number of rotatable bonds and the number of rigid bonds are linked with the intestinal absorption and showed that all the hits may have good intestinal absorption. *In silico* assessment of the hits also showed that they have very good pharmacokinetic properties based on their physicochemical values. The structures of the best virtual hits with their docking scores are given in the Fig. 10. The structures of other virtual hits are provided in ESI S1.†

### 3.5 Molecular dynamics simulation

The molecular dynamics simulations offer a more precise estimate of the interactions, energetic and the conformational changes of the ligands at the binding site of the protein and such studies actually simulate the biological environment which is more advantageous than the *in vacuo* conditions. In order to gain deeper insights into the exact mode of the binding of the best virtual hits and to evaluate the energetic of the ligand enzyme interactions more accurately the MD simulation studies were undertaken. The docked complexes of the panC with the potential hits (STOCK1N-60270, STOCK1N-63040, STOCK1N-44424 and STOCK1N-63231) with the top ranked conformers were

used in the 10 ns MD simulations. The results of the MD simulation are evaluated through the measurement of root mean square deviation (RMSD), root mean square fluctuation (RMSF), number of H-bonds formed between the ligand and the key residues and the energetic of each complex. In case of the RMSD measurement the deviations from the original starting positions of the backbone atoms or the ligand atoms are measured during entire MD simulation. Lower deviations are indicative of the better stability. The average RMSD values for the complexes of STOCK1N IDs 60270, 63040, 44424 and 63231 were  $0.265 \pm 0.002$ ,  $0.289 \pm 0.002$ ,  $0.228 \pm 0.003$  and  $0.1236 \pm 0.006$  respectively. This suggests better stability of the STOCK1N-63231 than the other hits. The average RMSD values for the ligands in these complexes 60270, 63040, 44424 and 63231 were  $0.165 \pm 0.002$ ,  $0.189 \pm 0.003$ ,  $0.178 \pm 0.001$  and  $0.108 \pm 0.004$  respectively, which suggests the stability of the hit 63231 better than the other hits. The results of the MD studies with RMSD are provided in Fig. 11.

The RMSF is a measure of elasticity of the protein under the investigation in terms of the fluctuations in the protein backbone during the MD simulation. The results of the RMSF evaluations are provided in Fig. 12.

The RMSF evaluations suggest that the backbone fluctuations are minimal in case of the complex of 63231 suggesting its better stability than the other complexes. The minimal fluctuations here may be attributed to the favorable interactions at the active site. The non bonded interactions such as hydrogen bonds between the ligand and the key residues at the binding site of the protein contribute to the binding affinity and activity of the ligand. The more number of hydrogen bonds between hydrogen bond donor-acceptor






Fig. 13 Hydrogen bonds formed with the chosen virtual hits during entire MD simulation (A) 44424; (B) 60270; (C) 63040; and (D) 63231.

atoms of the ligand with such atoms of residues in binding site suggests the more binding affinity. In MD simulation studies the maximum number of hydrogen bonds formed between the ligands 60270, 63040, 44424 and 63231 and residues at binding site are 11, 15, 10 and 3 respectively. The average number of hydrogen bonds formed during entire simulation for the ligands 60270, 63040, 44424 and 63231 are 5.1, 2.1, 1.6 and 1.8 respectively suggesting the better binding affinity of the complex 60270. The results of hydrogen bond analysis are provided in Fig. 13.

The docking studies also support the evaluation of hydrogen bonds. Other non bonded interaction energies such as the short-range coulombic and the Lennard-Jones and the total interaction energies were also computed to understand the strength of the interaction between compounds under study and the panC. The average short-

range coulombic and Lennard-Jones and total interaction energies are given in Table 5. The results suggest that only in compound 44424 the short range coulombic interactions occur.

This interaction may be due to the presence of the ionizable carboxylate groups extended through the pentyl chain. The Lennard-Jones (LJ) interaction energy estimate suggest that the compound 60270 has the highest LJ interaction energy which may be contributing in the highest activity of this compound. The results of energy evaluations are also provided in Fig. 14.

On the basis of these MD results such as the number of hydrogen bonds formed during the simulation, RMSD, RMSF and the corresponding energetics of the simulation, the virtual hit **STOCK1N 60270** could be the best ligand as a potential inhibitor of modeled PanC.



Table 5 Energy evaluation for hit molecules

Compound STOCK1N ID	Short-range coulombic interaction energy (kJ mol <sup>-1</sup> )	Short-range Lennard-Jones interaction energy (kJ mol <sup>-1</sup> )	Total short-range interaction energy (kJ mol <sup>-1</sup> )
60270	0	-149.88 ± 4	-4.794482 × 10 <sup>5</sup>
63040	0	-229.108 ± 6.7	-4.798895 × 10 <sup>5</sup>
44424	-87.6557 ± 6.7	-174.416 ± 5.6	-4.719041 × 10 <sup>5</sup>
63231	-80.0583 ± 1.9	-177.261 ± 4	-3.89751 × 10 <sup>5</sup>




Fig. 14 Energy evaluation between the protein and the hit molecules. (A) The short range coulombic interaction energy; (B) the short range Lennard-Jones interaction energy.

## 4 Conclusion

In the present study the novel comparative pathway analysis approach was employed to find the unique metabolic pathways and to identify the key enzymes in such pathways in the *H. pylori*. The study has shown that the pantothenate synthetase of the *H. pylori* can serve as the potential drug target as it is essential for its survival. The combined structure-based drug design approaches namely homology modeling, molecular docking, pharmacophore modeling, virtual screening and molecular dynamics simulations provided the virtual hits with better structural, binding, pharmacokinetic and toxicity

features. The virtual hits **STOCK1N-60270**, **63040**, **44424** and **63231** has been identified as potential *H. pylori* specific panC inhibitors. Based on the docking and MD studies the virtual hit **STOCK1N 60270** which is a succinic acid derivative could serve as a lead for further development of potential inhibitors of the *H. pylori* specific panC. These virtual hit could be potentially beneficial in gastric carcinomas due to underlying *H. pylori* infections.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The authors SAA, HMA and AAA would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for funding through the Research Group Project No. RG-1439-010. Authors are thankful to Dr Zahid Zaheer, Principal, Y. B. Chavan College of Pharmacy, Dr Rafiq Zakaria Campus, Aurangabad 431 001 (M.S.), India for providing the laboratory facility.

## References

- 1 W.-L. Chang, Y.-C. Yeh and B.-S. Sheu, *J. Biomed. Sci.*, 2018, **25**, 68.
- 2 *Cancer (Fact sheet N 297)*, World Health Organization, February 2014, retrieved 2009-05-11, <http://www.who.int/news-room/fact-sheets/detail/cancer>.
- 3 J.-Y. Wu, C.-C. Cheng, J.-Y. Wang, D.-C. Wu, J.-S. Hsieh, S.-C. Lee and W.-M. Wang, *PLoS One*, 2014, **9**, e84158.
- 4 Y. Yamaoka, *Helicobacter pylori: molecular genetics and cellular biology*, Horizon Scientific Press, 2008.
- 5 T. T. Binh, V. P. Tuan, H. D. Q. Dung, P. H. Tung, T. D. Tri, N. P. M. Thuan, V. Van Khien, P. Q. Hoan, R. Suzuki and T. Uchida, *Gut Pathog.*, 2017, **9**, 46.
- 6 A. Savoldi, E. Carrara, D. Y. Graham, M. Conti and E. Tacconelli, *Gastroenterology*, 2018, **155**, 1372–1382.
- 7 F. Mégraud, *Ther. Adv. Gastroenterol.*, 2012, **5**, 103–109.
- 8 K. E. L. McColl and E. El-Omar, *Keio J. Med.*, 2002, **51**, 53–56.
- 9 R. Leonardi and S. Jackowski, *EcoSal Plus*, 2007, 1–18.
- 10 L. M. Brown, *Epidemiol. Rev.*, 2000, **22**, 283–297.
- 11 J.-F. Tomb, O. White, A. R. Kerlavage, R. A. Clayton, G. G. Sutton, R. D. Fleischmann, K. A. Ketchum, H. P. Klenk, S. Gill and B. A. Dougherty, *Nature*, 1997, **389**, 412.



- 12 J.-C. Rain, L. Selig, H. De Reuse, V. Battaglia, C. Reverdy, S. Simon, G. Lenzen, F. Petel, J. Wojcik and V. Schächter, *Nature*, 2001, **409**, 211.
- 13 R. Häuser, A. Ceol, S. V. Rajagopala, R. Mosca, G. Siszler, N. Wermke, P. Sikorski, F. Schwarz, M. Schick and S. Wuchty, *Mol. Cell. Proteomics*, 2014, **13**, 1318–1329.
- 14 <https://www.ebi.ac.uk/>, accessed on 31 October 2018.
- 15 <https://www.uniprot.org/uniprot/P56061>, accessed on 31 October 2018.
- 16 V. K. Vyas, R. D. Ukawala, M. Ghate and C. Chintha, *Indian J. Pharm. Sci.*, 2012, **74**, 1.
- 17 X.-Y. Meng, H.-X. Zhang, M. Mezei and M. Cui, *Curr. Comput.-Aided Drug Des.*, 2011, **7**, 146–157.
- 18 D. K. Yadav, R. Rai, N. Kumar, S. Singh, S. Misra, P. Sharma, P. Shaw, H. Pérez-Sánchez, R. L. Mancera and E. H. Choi, *Sci. Rep.*, 2016, **6**, 38128.
- 19 R. Gaur, D. K. Yadav, S. Kumar, M. P. Darokar, F. Khan and R. Singh Bhakuni, *Curr. Top. Med. Chem.*, 2015, **15**, 1003–1012.
- 20 B. S. Kumar, A. Kumar, J. Singh, M. Hasanain, A. Singh, K. Fatima, D. K. Yadav, V. Shukla, S. Luqman and F. Khan, *Eur. J. Med. Chem.*, 2014, **86**, 740–751.
- 21 D. Kumar Yadav, K. Kalani, A. K. Singh, F. Khan, S. K. Srivastava and A. B. Pant, *Curr. Med. Chem.*, 2014, **21**, 1160–1170.
- 22 D. K. Yadav, P. Sharma, S. Misra, H. Singh, R. L. Mancera, K. Kim, C. Jang, M. Kim, H. Pérez-Sánchez and E. H. Choi, *Arch. Pharmacol. Res.*, 2018, **41**, 1178–1189.
- 23 H. Sun, J. Zhu, F. Chen, S. Zhang, Y. Zhang and Q. You, *Eur. J. Med. Chem.*, 2011, **46**, 3942–3952.
- 24 A. Hussain and C. Verma, *J. Cancer Res. Ther.*, 2019, DOI: 10.4103/jcrt.JCRT\_47\_18.
- 25 S. Pal, V. Kumar, B. Kundu, D. Bhattacharya, N. Preethy, M. Prashanth Reddy and A. Talukdar, *Comput. Struct. Biotechnol. J.*, 2019, **17**, 291–310.
- 26 G. Eren, A. Bruno, S. Guntekin-Ergun, R. Cetin-Atalay, F. Ozgencil, Y. Ozkan, M. Gozelle, S. Gozde Kaya and G. Costantino, *J. Mol. Graphics Modell.*, 2019, **89**, 60–73.
- 27 X. Feng, W. Jia, X. Liu, Z. Jing, Y. Liu, W. Xu and X. Cheng, *Comput. Biol. Chem.*, 2019, **78**, 178–189.
- 28 F. Cheng, W. Li, G. Liu and Y. Tang, *Curr. Top. Med. Chem.*, 2013, **13**, 1273–1289.
- 29 D. K. Yadav, S. Kumar, H. S. Saloni, M. Kim, P. Sharma, S. Misra and F. Khan, *Drug Des., Dev. Ther.*, 2017, **11**, 1859.
- 30 R. Zheng and J. S. Blanchard, *Biochemistry*, 2001, **40**, 12904–12912.
- 31 R. Caspi, H. Foerster, C. A. Fulcher, P. Kaipa, M. Krummenacker, M. Latendresse, S. Paley, S. Y. Rhee, A. G. Shearer, C. Tissier, T. C. Walk, P. Zhang and P. D. Karp, *Nucleic Acids Res.*, 2008, **36**, D623–D631.
- 32 P. D. Karp, S. M. Paley, M. Krummenacker, M. Latendresse, J. M. Dale, T. J. Lee, P. Kaipa, F. Gilham, A. Spaulding, L. Popescu, T. Altman, I. Paulsen, I. M. Keseler and R. Caspi, *Briefings Bioinf.*, 2010, **11**, 40–79.
- 33 R. Zhang, H. Ou and C. Zhang, *Nucleic Acids Res.*, 2004, **32**, D271–D272.
- 34 S. Pundir, M. J. Martin and C. O'Donovan, in *Protein Bioinformatics*, Springer, 2017, pp. 41–55.
- 35 G. Hu and L. Kurgan, Sequence Similarity Searching, *Curr. Protoc. Protein Sci.*, 2018, **13**, e71, DOI: 10.1002/cpps.71.
- 36 *Molecular Operating Environment (MOE), 2014.09*, Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2014.
- 37 P. Labute, *J. Comput. Chem.*, 2008, **29**, 1693–1698.
- 38 M. R. Anguru, A. K. Taduri, R. D. Bhoomireddy, M. Jojula and S. K. Gunda, *Chem. Cent. J.*, 2017, **11**, 68.
- 39 M. Kumar, B. Makhil, V. K. Gupta and A. Sharma, *J. Mol. Graphics Modell.*, 2014, **50**, 1–9.
- 40 M. Narender, K. Umasankar, J. Malathi, A. R. Reddy, K. R. Umadevi, A. V. N. Dusthacker and K. V. Rao, *Bioorg. Med. Chem. Lett.*, 2016, **26**, 836–840.
- 41 G. Samala, P. B. Devi, S. Saxena, N. Meda, P. Yogeewari and D. Sriram, *Bioorg. Med. Chem.*, 2016, **24**, 1298–1307.
- 42 P. B. Devi, G. Samala, J. P. Sridevi, S. Saxena, M. Alvala, E. G. Salina, D. Sriram and P. Yogeewari, *ChemMedChem*, 2014, **9**, 2538–2547.
- 43 S. Rampogu, M. Son, A. Baek, C. Park, R. M. Rana, A. Zeb, S. Parameswaran and K. W. Lee, *Comput. Biol. Chem.*, 2018, **74**, 327–338.
- 44 F. Cheng, W. Li, G. Liu and Y. Tang, *Curr. Top. Med. Chem.*, 2013, **13**, 1273–1289.
- 45 A. Kumar, S. Roy, S. Tripathi and A. Sharma, *J. Biomol. Struct. Dyn.*, 2016, **34**, 239–249.
- 46 D. Lagorce, O. Sperandio, H. Galons, M. A. Miteva and B. O. Villoutreix, *BMC Bioinf.*, 2008, **9**, 396.
- 47 C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, *Adv. Drug Delivery Rev.*, 1997, **23**, 3–25.
- 48 D. F. Veber, S. R. Johnson, H.-Y. Cheng, B. R. Smith, K. W. Ward and K. D. Kopple, *J. Med. Chem.*, 2002, **45**, 2615–2623.
- 49 A. Hospital, J. R. Goñi, M. Orozco and J. L. Gelpi, *Adv. Appl. Bioinf. Chem.*, 2015, **8**, 37.
- 50 H. J. C. Berendsen, D. van der Spoel and R. van Drunen, *Comput. Phys. Commun.*, 1995, **91**, 43–56.
- 51 J. Huang, S. Rauscher, G. Nawrocki, T. Ran, M. Feig, B. L. de Groot, H. Grubmüller and A. D. MacKerell Jr, *Nat. Methods*, 2017, **14**, 71.
- 52 B. Hess, H. Bekker, H. J. C. Berendsen and J. G. E. M. Fraaije, *J. Comput. Chem.*, 1997, **18**, 1463–1472.
- 53 H. G. Petersen, *J. Chem. Phys.*, 1995, **103**, 3668–3679.
- 54 R. A. Laskowski, M. W. MacArthur, D. S. Moss and J. M. Thornton, *J. Appl. Crystallogr.*, 1993, **26**, 283–291.
- 55 M. Wiederstein and M. J. Sippl, *Nucleic Acids Res.*, 2007, **35**, W407–W410.
- 56 M. U. Johansson, V. Zoete, O. Michielin and N. Guex, *BMC Bioinf.*, 2012, **13**, 173.

